- Home
- PARR vs ANAB Comparison
PARR vs ANAB Comparison
Compare PARR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PARR
- ANAB
- Stock Information
- Founded
- PARR 1984
- ANAB 2005
- Country
- PARR United States
- ANAB United States
- Employees
- PARR N/A
- ANAB N/A
- Industry
- PARR Integrated oil Companies
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- PARR Energy
- ANAB Health Care
- Exchange
- PARR Nasdaq
- ANAB Nasdaq
- Market Cap
- PARR 795.7M
- ANAB 759.5M
- IPO Year
- PARR N/A
- ANAB 2017
- Fundamental
- Price
- PARR $22.13
- ANAB $22.00
- Analyst Decision
- PARR Buy
- ANAB Buy
- Analyst Count
- PARR 7
- ANAB 10
- Target Price
- PARR $22.96
- ANAB $42.25
- AVG Volume (30 Days)
- PARR 1.5M
- ANAB 559.5K
- Earning Date
- PARR 05-06-2025
- ANAB 05-05-2025
- Dividend Yield
- PARR N/A
- ANAB N/A
- EPS Growth
- PARR N/A
- ANAB N/A
- EPS
- PARR N/A
- ANAB N/A
- Revenue
- PARR $7,738,658,000.00
- ANAB $111,872,000.00
- Revenue This Year
- PARR N/A
- ANAB N/A
- Revenue Next Year
- PARR N/A
- ANAB $9.72
- P/E Ratio
- PARR N/A
- ANAB N/A
- Revenue Growth
- PARR N/A
- ANAB 387.20
- 52 Week Low
- PARR $11.86
- ANAB $12.21
- 52 Week High
- PARR $27.45
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- PARR 70.92
- ANAB 62.95
- Support Level
- PARR $19.28
- ANAB $20.50
- Resistance Level
- PARR $22.55
- ANAB $22.84
- Average True Range (ATR)
- PARR 0.91
- ANAB 1.22
- MACD
- PARR 0.05
- ANAB 0.15
- Stochastic Oscillator
- PARR 78.39
- ANAB 86.53
About PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).